Dr Suraiya Dubash specialises in Lung cancer, Mesothelioma, Thymic cancer, Thymoma. Chemotherapy, Immunotherapy, Biological/ Targeted therapies, Radiotherapy, Stereotactic Radiotherapy for Lung cancers and Oligometastases.
Dr Suraiya Dubash is a Consultant in Clinical Oncology at Mount Vernon Cancer Centre, specialising in the treatment and care of patients with lung cancer, thymoma, and thymic cancers. She leads the stereotactic radiotherapy (SABR) service at Mount Vernon and holds an Honorary Clinical Senior Lecturer position at Imperial College London, where she collaborates with the cancer imaging group to advance oncology through research, innovation, and education.
Dr Dubash studied medicine at St. Bartholomew’s and the Royal London Hospital before completing her oncology training at Imperial College London and Mount Vernon Cancer Centre. She went on to earn a PhD in Clinical Cancer Imaging at Imperial College London, with research focused on functional imaging (PET/CT and MRI), biomarker and radiopharmaceutical development, and the application of AI in oncology.
Her commitment to advancing cancer care is reflected in her active role in clinical research. She has served as Principal Investigator for multiple national portfolio clinical trials and has advised pharmaceutical companies on the development of novel cancer therapies. Her work has been recognised with awards from the NCRI, BNMS, and JNM, among others, and she has published extensively in high-impact, peer-reviewed journals.
Her clinical expertise includes chemotherapy, biological/targeted therapy, immunotherapy, and radiotherapy. She is proficient in state-of-the-art radiotherapy techniques, including intensity modulated radiotherapy (IMRT), volumetric modulated arc therapy (VMAT), image guided radiotherapy (IGRT), and stereotactic radiotherapy (SABR) on both Linac and Cyberknife platforms.